新冠病毒感染中的全假性血小板减少症：致死性动脉血栓形成的先兆？
Pan-Pseudothrombocytopenia in COVID-19: A Harbinger for Lethal Arterial Thrombosis?
作者信息
Kuhlman Patrick, Nasim Julio, Goodman Michael
机构信息
is a PGY-6 Resident, and Michael Goodman is an Assistant Professor, both in the Hematology-Oncology Fellowship Program; is a PGY-5 Resident in the Infectious Disease Fellowship Program; all at Wake Forest University School of Medicine in Salem, North Carolina, and the W.G. (Bill) Hefner VA Medical Center in Salisbury, North Carolina.
出版信息
Fed Pract. 2020 Aug;37(8):354-358. doi: 10.12788/fp.0032.
Abstract
Pseudothrombocytopenia in the setting of COVID-19-associated coagulopathy prompts the question whether it is representative of increased platelet aggregation activity in vivo.
摘要
新型冠状病毒肺炎相关凝血病背景下的假性血小板减少症引发了一个问题，即它是否代表体内血小板聚集活性增加。
相似文献
1
Pan-Pseudothrombocytopenia in COVID-19: A Harbinger for Lethal Arterial Thrombosis?新冠病毒感染中的全假性血小板减少症：致死性动脉血栓形成的先兆？
Fed Pract. 2020 Aug;37(8):354-358. doi: 10.12788/fp.0032.
2
Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia.筛查假性血小板减少症中血小板计数的EDTA依赖性偏差及血小板分布直方图异常。
Scand J Clin Lab Invest. 1997 Nov;57(7):629-36. doi: 10.3109/00365519709055287.
3
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.阿昔单抗治疗期间假性血小板减少症的发生情况及临床意义。
J Am Coll Cardiol. 2000 Jul;36(1):75-83. doi: 10.1016/s0735-1097(00)00688-4.
4
Amikacin can be added to blood to reduce the fall in platelet count.阿米卡星可加入血液中，以减少血小板计数下降。
Am J Clin Pathol. 2011 Oct;136(4):646-52. doi: 10.1309/AJCPMON79QKQKRBT.
5
Accurate platelet counting in an insidious case of pseudothrombocytopenia.隐匿性假性血小板减少症病例中的准确血小板计数
Clin Chem Lab Med. 1999 Nov-Dec;37(11-12):1063-6. doi: 10.1515/CCLM.1999.155.
6
Prevalence and course of pseudothrombocytopenia in outpatients.门诊假性血小板减少症的患病率和病程。
Clin Chem Lab Med. 2011 Jan;49(1):111-4. doi: 10.1515/CCLM.2011.013. Epub 2010 Oct 20.
7
[Pseudothrombocytopenia: incidence, causes and methods of detection].[假性血小板减少症：发病率、病因及检测方法]
Sangre (Barc). 1991 Jun;36(3):197-200.
8
[EDTA-dependent pseudothrombocytopenia in association with myasthenia gravis].
Rinsho Shinkeigaku. 1989 Jul;29(7):927-9.
9
Effective prevention of pseudothrombocytopenia in feline blood samples with the prostaglandin I2 analogue Iloprost.使用前列腺素I2类似物伊洛前列素有效预防猫血样中的假性血小板减少症。
BMC Vet Res. 2015 Aug 6;11:183. doi: 10.1186/s12917-015-0510-x.
10
Thrombocytopenia associated with c7E3 Fab (abciximab).与c7E3 Fab（阿昔单抗）相关的血小板减少症。
Ann Hematol. 2002 Feb;81(2):76-9. doi: 10.1007/s00277-001-0414-7. Epub 2002 Jan 18.
引用本文的文献
1
EDTA-Induced Pseudothrombocytopenia up to 9 Months after Initial COVID-19 Infection Associated with Persistent Anti-SARS-CoV-2 IgM/IgG Seropositivity.初始 COVID-19 感染后长达 9 个月时 EDTA 诱导的假性血小板减少症与持续的抗 SARS-CoV-2 IgM/IgG 血清阳性相关。
Lab Med. 2022 Mar 7;53(2):206-209. doi: 10.1093/labmed/lmab050.
2
Massive Platelet Clumping on Peripheral Blood Smear and Pseudothrombocytopenia in a Patient with COVID-19.一名新冠肺炎患者外周血涂片上出现大量血小板聚集及假性血小板减少症
Balkan Med J. 2021 May;38(3):194. doi: 10.5152/balkanmedj.2021.20229.
3
Hematological Abnormalities in COVID-19: A Narrative Review.新型冠状病毒肺炎相关血液学异常：一项叙述性综述。
Am J Trop Med Hyg. 2021 Feb 19;104(4):1188-1201. doi: 10.4269/ajtmh.20-1536.
4
Pseudothrombocytopenia-A Review on Causes, Occurrence and Clinical Implications.假性血小板减少症——病因、发生率及临床意义综述
J Clin Med. 2021 Feb 4;10(4):594. doi: 10.3390/jcm10040594.
本文引用的文献
1
2
Transient appearance of EDTA dependent pseudothrombocytopenia in a patient with 2019 novel coronavirus pneumonia.2019 新型冠状病毒肺炎患者中出现的 EDTA 依赖性假性血小板减少症的一过性表现。
Platelets. 2020 Aug 17;31(6):825-826. doi: 10.1080/09537104.2020.1760231. Epub 2020 May 5.
3
COVID-19 and its implications for thrombosis and anticoagulation.新型冠状病毒肺炎及其对血栓形成和抗凝的影响。
Blood. 2020 Jun 4;135(23):2033-2040. doi: 10.1182/blood.2020006000.
4
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.国际血栓与止血学会（ISTH）关于新冠病毒病（COVID-19）凝血病识别与管理的临时指南。
J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.
5
Prone Position in Management of COVID-19 Patients; a Commentary.COVID-19患者管理中的俯卧位；一篇评论
Arch Acad Emerg Med. 2020 Apr 11;8(1):e48. eCollection 2020.
6
Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.严重 COVID-19 感染发病机制中的补体相关微血管损伤和血栓形成：五例报告。
Transl Res. 2020 Jun;220:1-13. doi: 10.1016/j.trsl.2020.04.007. Epub 2020 Apr 15.
7
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
8
Etiologies of Thrombocytopenia in the Community Hospital: The Experience of 1 Hematologist.社区医院血小板减少症的病因：一位血液学家的经验。
Am J Med. 2020 May;133(5):e183-e186. doi: 10.1016/j.amjmed.2019.10.027. Epub 2019 Nov 9.
9
Pseudothrombocytopenia due to Platelet Clumping: A Case Report and Brief Review of the Literature.血小板聚集导致的假性血小板减少症：一例报告及文献简要综述
Case Rep Hematol. 2016;2016:3036476. doi: 10.1155/2016/3036476. Epub 2016 Dec 4.
10
A case of EDTA-dependent pseudothrombocytopenia: simple recognition of an underdiagnosed and misleading phenomenon.一例乙二胺四乙酸（EDTA）依赖性假性血小板减少症：对一种诊断不足且具有误导性现象的简单识别
BMC Clin Pathol. 2014 May 1;14:19. doi: 10.1186/1472-6890-14-19. eCollection 2014.
Zotero 插件